TheBodyPro
@BodyPROHIV
The HIV resource for care providers and the HIV workforce. For the HIV community, check out @TheBodyDotCom
D2EFT 96-week data: Dual ART (DRV/r+DTG) outperformed SOC for 2nd-line #HIVTreatment—no emergent resistance, 85.7% suppressed <50 c/mL. No genotyping? Still effective. bit.ly/4kQWS65 #HIV #IDTwitter #IAS2025 #GlobalHealth @CIDJournal

New head-to-head data from a 96-week trial show DRV/r + DTG achieves superior viral suppression (~85.7%) versus SOC (~76.1%), with no emergent #Darunavir resistance—offering a potent 2‑drug option when genotyping isn’t available. bit.ly/4kQWS65 #HIVTreatment #D2EFT

Real-world data from OPERA: CAB/rilpivirine led to viral suppression in 85% of viremic patients within 6 months. Dr. Ricky Hsu highlights promise beyond trials—including women, older adults & those in the South. bit.ly/4514YmC #IAS2025 #HIVTreatment #LongActingART

Despite strong #PrEP awareness, many adolescent health providers report limited confidence in prescribing and managing it—just 68–76% feel comfortable, per a Maryland survey. bit.ly/3DccuRZ #HIVPrevention #AdolescentHealth @BenYoung_PhD

Frailty, #CognitiveDecline, falls, poly-pharmacy — geriatric syndromes overlap & hit earlier for people living with #HIV. Dr Zhabokritsky: “Studies show frailty is dynamic — prevention & reversal are possible with a comprehensive approach.” bit.ly/4nrCV8b @UofT_DoM

“In low- & middle-income countries, U.S. cuts mean > 75% of HIV service funding has disappeared, shutting down key-population programs.” – Evans Adofo, Liberia. 55% of new #HIV diagnoses now come from key populations. bit.ly/40tdNnQ #IAS2025 #GlobalHIV @adofo_evans
New research suggests that universal #depression screening & treatment among people with #HIV could boost national viral suppression rates by 5%. bit.ly/43zRpt6 #HIVCare #MentalHealth @DrLindaJKoenig

New CDC #HIV nPEP guidelines reinforce U=U — viral suppression = no transmission risk for sex, clarify when #nPEP is not needed if source VL <200 copies/mL, & call for risk-based case-by-case decisions for needle sharing.➜ bit.ly/40LppTd #nPEP #PrEP #IDTwitter

Should people with #HIV interrupt treatment for cure research? ATI trials pose long-term risks, but most lack follow-up beyond 10 years. bit.ly/3PV5rzC #HIVResearch #Bioethics #AntiretroviralTherapy @amaya_pb @TheLancetHIV @UCSD

“2024 has been a landmark year for HIV prevention—standing ovations and @NEJM publications—thanks to the PURPOSE studies.”—@drlaurajwaters at #CROI2025 on #SubQ lenacapavir vs oral #PrEP in cis women, MSM & trans women. bit.ly/3Bypd0t #HIVPrevention #PrEP #PURPOSE
Study LNP X: Efficient #mRNA delivery to resting T-cells to reverse #HIV latency LNP X enables potent, non-toxic mRNA transfection of resting CD4+ T-cells—advancing latency reversal strategies without activation. bit.ly/4eevj53 #HIVResearch #HIVCure @TheDohertyInst
#CHEFSHIV: In this randomized study of Bay Area @ProjectOpenHand clients with #HIV, improved food access led to better physical & mental health outcomes. bit.ly/4jFUy22 #Nutrition #FoodAsMedicine #MentalHealthMatters #HealthyFood @UCSF @JIDJournal

Long-acting CAB/RPV maintains viral suppression (94–96%) through 2 years in #HIV-positive patients. Should we expand use to those with detectable viremia? bit.ly/4kJBmBs #CROI2025 #HIV #LongActingART @PaulSaxMD

“A cure strategy… will work differently based on how the host responds due to their age & the status of the immune system.” — Alan Landay, PhD. How should aging shape #HIVCure design? Read the Q&A → bit.ly/3Ft5JM5 #HealthyLifestyle #CROI2025 #HIV #Aging @utmbhealth

Dr Benjamin Young- “Only 20% of people who met guideline criteria for #Statin use received a prescription.” There is a striking underuse of #Statins in both HIV-positive & #HIV-negative patients. bit.ly/42KJvi7 #PreventiveMedicine #CVDHealth @Equity_WEA #CardioTwitter

Study Insight: Congenital #Syphilis has roughly doubled since 2019, largely in cis women who have sex with men. Reduced #STITesting, awareness, condom use, & a Bicillin-LA shortage are all fueling the rise. More details: bit.ly/4mSGaW4
Study: Routine #HIV RNA Testing in Oral PrEP Users Questioned. Up to 9,900 RNA tests needed to detect one missed early case—minimal added value over Ag/Ab. Findings challenge 2021 CDC guidance. bit.ly/3Syke4y #InfectiousDiseases #HIVPrevention #PrEP @CDCgov

ATHENA data challenge the universality of early #HIVTreatment. “Controllers off ART had fewer non-AIDS events—including fractures & #CKD—than standard ART users,” says @drlaurajwaters. bit.ly/4cRFMT2 #HIVResearch #Antiretrovirals

“More cuts mean more illness.” With zero state #HIVPrevention funding in MS, AL, and LA, federal clawbacks are devastating outreach—especially for patients facing housing and care barriers. bit.ly/42TTnpM #HIVPrevention #HousingShortage #RuralHealth

As people with #HIV live longer, #PreventiveCare is essential—but time is tight. Experts from the US & UK discuss how to balance screenings, #HIVCare, vaccines & #HealthyLifestyle counseling. bit.ly/3G2Pw0C @drlaurajwaters @MonicaGandhi9